Zhone Technologies (NASDAQ:ZHNE) has lost 2.13% or five cents to settle at $2.30 a share with a volume of 29,067 shares, compared to its average three-month volume of 89,000 shares. Company has a market cap of $70 million and outstanding common shares of 30.49 million.
Zhone Technologies, Inc. (Zhone) designs, develops and manufactures communications network equipment for telecommunications, wireless and cable operators worldwide. Its products and solutions allow network service providers to migrate from traditional circuit-based networks to packet-based networks. In addition to its product offerings, Zhone launched the flagship MXK IP Multi-service Terabit Access Concentrator (MXK) and multiple new Optical Line Terminal (OLT) and outdoor units during the year ended December 31, 2009.
CoreLogic Inc. (NYSE:CLGX) has gained 0.4% or seven cents a share to settle at $17.49 with a volume of 335,000 shares, compared to its average three-month volume of 530,000 shares. Company has a market cap of $2.05 billion and 117 million common outstanding shares. For the past 52 weeks the stock has been trading between $17.07 and $21.50 with a beta of 0.81.
CoreLogic, Inc., formerly The First American Corporation is a United States company. It combines the United States property, mortgage, finance, fraud, credit and consumer data resources with analytics and business intelligence.
Seattle Genetics, Inc. (NASDAQ:SGEN) this $1.65 billion company has been relatively unchanged today at $14.60 a share. Company traded total of 386,000 shares compared to its average three-month volume of 1.18 million shares. The stock is trading with a beta of 1.15 and has 113 million common outstanding shares.
Seattle Genetics, Inc. (Seattle Genetics) is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. In August 2009, the Company completed enrollment to a trial of its lead product candidate, brentuximab vedotin (SGN-35), for patients with relapsed or refractory Hodgkin lymphoma under a special protocol assessment (SPA) with the United States Food and Drug Administration (FDA). Brentuximab vedotin is empowered by the Company's antibody-drug conjugate (ADC) technology comprising synthetic drugs and linkers for attaching the drugs to monoclonal antibodies.
Cynosure, Inc. (NASDAQ:CYNO) has lost 1.31% or $.70 a share to settle at $12.79 a share with a volume of 24,337. For the past 52 weeks the stock has been trading between $8.80 and $14.50 a share with an average volume of 52,500 shares. Company has a market cap of $161 million with 12.60 million in common outstanding.
Cynosure, Inc. (Cynosure) develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular lesions and pigmented lesions, as well as multi-colored tattoos, temporarily reduce the appearance of cellulite, treat wrinkles, skin texture, skin discoloration and skin tightening, and to perform minimally invasive procedures for LaserBodySculpting for the removal of unwanted fat.
China HGS Real Estate (NASDAQ:HGSH) has pummeled 20.43% or $.57 a share to settle at $2.22 with a volume of 8650 shares. For the past 52 weeks the stock has been trading between $2.12 and $5.00 a share with an average volume of 3759 shares. Company has a market cap of $100 million and has 45 million in common outstanding shares.
China HGS Real Estate Inc. (China HGS), along with its subsidiaries and variable interest entity (VIE), engages in real estate development, in the construction and sale of residential apartments, car parks and commercial properties. The Company conducts all of its business through its Shaanxi Guangsha Investment and Development Group Co., Ltd. (Guangsha) subsidiary.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any current or recent stocks listed in this stock news report
